Core Insights - Bayer's participation in the China International Import Expo (CIIE) has evolved significantly over the past eight years, reflecting a long-term commitment to the Chinese market and innovation in health consumer products [1][3][12] Group 1: Evolution of CIIE - The CIIE has transformed from a platform focused on importing foreign products to a comprehensive international stage that facilitates technology exchange, cross-industry collaboration, and entrepreneurial opportunities [3] - Bayer's role has shifted from merely showcasing products to actively linking with business partners and fostering innovation through collaboration [3][4] - The future potential of CIIE lies in global resource integration and innovation collaboration, with Bayer aiming to deepen its connection with the Chinese market [3] Group 2: Product and Supply Chain Strategy - Bayer's strategy has shifted from simply importing products to focusing on the specific needs of Chinese consumers, emphasizing tailored product development [5][9] - The company's R&D capabilities in China are increasingly significant within its global framework, with a focus on optimizing projects based on local market demands [5][7] - Bayer's supply chain has evolved from reliance on traditional shipping methods to utilizing the China-Europe Railway Express, enhancing logistics efficiency and reducing risks [7][9] Group 3: Innovation and Collaboration - Bayer is exploring digitalization and innovative collaboration models, particularly in the context of AI, which is seen as a tool to enhance business intelligence [9][10] - The company is prioritizing partnerships with local firms to develop products that meet specific consumer needs, such as children's calcium supplements and skincare products [10] - Bayer is adjusting its multi-channel strategy to optimize consumer experience across different platforms, addressing the coexistence of traditional and emerging e-commerce channels in China [10][12]